Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA)

If you're looking around for falling knives to catch, may I recommend Vanda? The stock can never get any liftoff because royalties from their single product Fanapt have plateaued under 1M/quarter, and their pipeline consists of a single medication in development for N24SWD. Don't ask.

Of course, some dingbat at Novartis saved Vanda from certain destruction by agreeing to pay 200M for the rights to Fanapt, in one of the dopiest mis-steps by big pharma I've seen. The lion's share of that cash, 188M, remains in Vanda's coffers as of the end of Q2. At the close today, Vanda's market cap was 190M. It's certainly possible that continuing broad market collapse will drag Vanda's cap way below cash. It happened in 2009 to a lot of biotechs and it's happening now to companies like Orexigen and Transcept. But if you bought a basket of those beaten down cash flush biotechs in 2009, you'd have been sitting very pretty a year later.

Vanda has bounced off cash a number of times and I've logged wins on the stock about 12 times in both directions over the last couple of years. Strangely, I've never actually bought the stock. Vanda has so little future with their current line-up that I'd be hesitant to risk real money unless the cash-cap discrepancy became extreme. Vanda always has the potential to pull an Insmed, blowing their cash hoard on a questionable acquisition.

A small cap with 195 million in cash, but it's a pharmaceutical which scares me. I been burned by other pharmaceuticals that looked promising but I'll go with it here in caps.

Vanda is a Biopharmaciutical company perfecting cures for central nervous disorders.Vanda is a young company trading at 29.4x earnings , 6.4x sales, 6.5x tangible book. Vanda has no long term debt and cash per share of $6.92. Seventy four large block owners own 81.40%.

They have $200 million in the bank and no debt. With the stock price around $200 million you are getting a profitable business for free, with significant upside potential.

VNDA chart trend since last summer s clear and next short term leg target IMO is $11. Fair value according to Morningstar and Hapoalim is $16 http://t.co/MNME5fO

See my other comments @ http://twitter.com/kampaakampaa/favorites

First I would like to state that; low priced stocks{penny] can show great percentage increases with just a few cents increase. Okay with that said. Pharmaceuticals are out of favor. Ginead is one example. The stock market is run on emotion and people are cautious. The new health bill has people wondering. Generics? Yes they have possible patents but there under testing, and we know it can take money and time to be shot down. Or it can be great. But here's the catch; risk, chance. This is not a bull market. Most people are cautious.

Hm, is in talks to be bought.

Aqcuisition or partnership

Plucked this from "UltraLong" who currently has a 98% accuracy rate. Holy Sh#% 98%?!?

This pharmaceutical has big spike on good news, but it's badly run and overvalued.

Thanks Ultralong for this, I love the chart!

VNDA

do to the mere fact of a potential billion dollar a year drug.

Greatly undervalued. A gamble that could either fizzle or be a 6-bagger. Not much on the downside, but a lot of potential upside.

Vanda Pharmaceuticals signs deal with Laboratory Corp. to sell genetic test

FDA approval of Fanapta will be decided on 7/27/08. There is no advisory panel for fanapta which is good news since advisory panel usually means theres some short comings. Overall research shows high chance of it being approved by the FDA and after that....caching

This stock is above it's 20- and 30-day moving average on the charts. They did not report any revenues for the end of last year and it is in the healthcare sector and the biotechnology and drugs industry. I have heard that the healthcare stocks are the ones to get into.

Vanda is expecting a decision on Fanapta, their schizophrenia drug, by late June. The drug performed well in Phase III clinical trials, with lower side effects than the presently prescribed drugs. Up until the decisoin is made, I think the buzz around this drug will push the stock price up over $6. It's a pretty risky play though, as this drug pretty much makes or breaks Vanda. Although their Q1 losses were less than expected, I don't think Vanda survives if Fanapta doesn't make it to market. But if it does, expect the stock to see a big jump in price. In the meantime, I think we'll see a steady creep upward as the hype around Fanapta grows.

As of close of business on 12/18/2007, this was a 5-star Morningstar stock trading at less than half it's Morningstar fair value.

Speculative schizophrenia drug that fills a niche that is not overcrowded. Potential FDA approval by mid 2008.